Pharma Synth Formulations Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 21-06-2024
- Paid Up Capital ₹ 5.00 M
as on 21-06-2024
- Company Age 31 Year, 28 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 18.00 Cr
as on 21-06-2024
- Satisfied Charges ₹ 6.03 Cr
as on 21-06-2024
- Revenue 2.06%
(FY 2023)
- Profit 3.06%
(FY 2023)
- Ebitda -8.29%
(FY 2023)
- Net Worth 10.66%
(FY 2023)
- Total Assets 0.88%
(FY 2023)
About Pharma Synth Formulations
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹18.00 Cr. The company has closed loans amounting to ₹6.03 Cr, as per Ministry of Corporate Affairs (MCA) records.
Arvind Gupta, Ramesh Jain, and Phoolwati Jain serve as directors at the Company.
- CIN/LLPIN
U74899DL1993PLC056231
- Company No.
056231
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
26 Nov 1993
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
East Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Pharma Synth Formulations Limited offer?
Pharma Synth Formulations Limited offers a wide range of products and services, including Common Disease Medicines, Oral Care Products, Healthcare Products & Aids, Health Drinks, Ayurvedic, Herbal Oils and Cosmetics, Aloe Vera Cosmetics.
Who are the key members and board of directors at Pharma Synth Formulations?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arvind Gupta  | Director | 26-Nov-1993 | Current |
| Ramesh Jain | Director | 26-Nov-1993 | Current |
| Phoolwati Jain | Director | 08-Mar-1994 | Current |
Financial Performance of Pharma Synth Formulations.
Pharma Synth Formulations Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.06% increase. The company also saw a slight improvement in profitability, with a 3.06% increase in profit. The company's net worth Soared by an impressive increase of 10.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pharma Synth Formulations?
In 2023, Pharma Synth Formulations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 20 Jan 2023 | ₹16.00 Cr | Open |
Sidbi Creation Date: 28 Mar 2022 | ₹2.00 Cr | Open |
Canara Bank Creation Date: 21 Sep 2007 | ₹0.46 M | Satisfied |
How Many Employees Work at Pharma Synth Formulations?
Pharma Synth Formulations has a workforce of 216 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pharma Synth Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pharma Synth Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
